| scholarly article | Q13442814 |
| P50 | author | Johan Bodegard | Q42773444 |
| Marcus Thuresson | Q60663764 | ||
| P2093 | author name string | Andreas Carlborg | |
| Lena Ferntoft | |||
| P2860 | cites work | Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects | Q38382192 |
| Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects | Q38775836 | ||
| A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy | Q40762464 | ||
| Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder | Q42869342 | ||
| The societal cost of bipolar disorder in Sweden | Q44052056 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
| Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies | Q44581952 | ||
| Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release | Q48222303 | ||
| Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study | Q48248419 | ||
| Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study | Q48466826 | ||
| Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. | Q51900824 | ||
| Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. | Q51902186 | ||
| Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. | Q51918322 | ||
| Increased Mortality Among Patients Admitted With Major Psychiatric Disorders | Q57516829 | ||
| Mortality of patients with mood disorders: follow-up over 34-38 years | Q74294155 | ||
| Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication | Q22253024 | ||
| The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research | Q24644519 | ||
| No health without mental health | Q28246161 | ||
| Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective | Q30483850 | ||
| Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP | Q30569917 | ||
| Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data | Q30701347 | ||
| Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. | Q33814003 | ||
| Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). | Q34000973 | ||
| Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative | Q34026000 | ||
| Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders | Q34186005 | ||
| Bipolar disorders: a review. | Q34270900 | ||
| Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study | Q34362623 | ||
| Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why. | Q34652340 | ||
| Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries | Q34796516 | ||
| Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression | Q35012213 | ||
| Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. | Q35057924 | ||
| Cardiovascular morbidity and mortality in bipolar disorder. | Q35313130 | ||
| Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders | Q36081021 | ||
| A retrospective study of clinical usage of quetiapine XR and quetiapine IR in outpatients with schizophrenia in Denmark | Q36387635 | ||
| Suboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioning | Q36557235 | ||
| Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study. | Q36618022 | ||
| Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden | Q36810120 | ||
| Bipolar depression: clinically missed, pharmacologically mismanaged | Q37078950 | ||
| Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study | Q37079066 | ||
| A systematic review of the evidence of the burden of bipolar disorder in Europe | Q37107103 | ||
| Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release | Q37307188 | ||
| Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment | Q37310164 | ||
| Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology | Q37426143 | ||
| The pharmacological treatment of bipolar disorder in primary care | Q37780228 | ||
| The role of quetiapine extended release in the treatment of bipolar depression | Q37787874 | ||
| P433 | issue | 1 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 13-21 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | Therapeutic advances in psychopharmacology | Q26842244 |
| P1476 | title | Characteristics of bipolar disorder patients treated with immediate- and extended-release quetiapine in a real clinical setting: a longitudinal, cohort study of 1761 patients | |
| P478 | volume | 5 |
Search more.